JP2017514483A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514483A5
JP2017514483A5 JP2016565257A JP2016565257A JP2017514483A5 JP 2017514483 A5 JP2017514483 A5 JP 2017514483A5 JP 2016565257 A JP2016565257 A JP 2016565257A JP 2016565257 A JP2016565257 A JP 2016565257A JP 2017514483 A5 JP2017514483 A5 JP 2017514483A5
Authority
JP
Japan
Prior art keywords
adenovirus
genome
albumin binding
protein
adenoviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514483A (ja
JP6639412B2 (ja
Filing date
Publication date
Priority claimed from EP14382162.7A external-priority patent/EP2940128A1/en
Application filed filed Critical
Publication of JP2017514483A publication Critical patent/JP2017514483A/ja
Publication of JP2017514483A5 publication Critical patent/JP2017514483A5/ja
Application granted granted Critical
Publication of JP6639412B2 publication Critical patent/JP6639412B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016565257A 2014-04-30 2015-04-30 アルブミン結合部分を含んでなるアデノウイルス Active JP6639412B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382162.7 2014-04-30
EP14382162.7A EP2940128A1 (en) 2014-04-30 2014-04-30 Adenovirus comprising an albumin-binding moiety
PCT/EP2015/059593 WO2015166082A1 (en) 2014-04-30 2015-04-30 Adenovirus comprising an albumin-binding moiety

Publications (3)

Publication Number Publication Date
JP2017514483A JP2017514483A (ja) 2017-06-08
JP2017514483A5 true JP2017514483A5 (cg-RX-API-DMAC7.html) 2018-06-14
JP6639412B2 JP6639412B2 (ja) 2020-02-05

Family

ID=50774820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565257A Active JP6639412B2 (ja) 2014-04-30 2015-04-30 アルブミン結合部分を含んでなるアデノウイルス

Country Status (12)

Country Link
US (3) US10604549B2 (cg-RX-API-DMAC7.html)
EP (2) EP2940128A1 (cg-RX-API-DMAC7.html)
JP (1) JP6639412B2 (cg-RX-API-DMAC7.html)
KR (1) KR102628234B1 (cg-RX-API-DMAC7.html)
CN (1) CN106471125B (cg-RX-API-DMAC7.html)
AU (1) AU2015254535B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016025297B1 (cg-RX-API-DMAC7.html)
CA (1) CA2946650C (cg-RX-API-DMAC7.html)
IL (1) IL248590B (cg-RX-API-DMAC7.html)
MX (1) MX381286B (cg-RX-API-DMAC7.html)
RU (1) RU2711371C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015166082A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
US20200330581A1 (en) * 2017-10-09 2020-10-22 Keith Black Oncolytic cancer immunotherapies and methods of use
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN113164538B (zh) * 2018-09-10 2025-03-04 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
CN113227361B (zh) 2018-11-21 2024-12-20 梅奥医学教育及研究基金会 腺病毒和使用腺病毒的方法
EP3911671A1 (en) 2019-04-29 2021-11-24 Mayo Foundation for Medical Education and Research Multivalent pd-l1 binding compounds for treating cancer
EP4010462A1 (en) 2019-08-05 2022-06-15 Mesoblast International Sàrl Cellular compositions comprising viral vectors and methods of treatment
US20240293487A1 (en) * 2020-03-25 2024-09-05 Jin-Woo Choi Immunoevasive anti-tumor adenovirus
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
CN116271066A (zh) * 2021-12-13 2023-06-23 康希诺生物股份公司 一种重组腺病毒载体疫苗吸入给药递送系统
CN114159556B (zh) * 2021-12-14 2023-06-16 中国人民解放军军事科学院军事医学研究院 一种用于腺病毒载体疫苗免疫增强的蛋白质纳米递送载体
WO2023120762A1 (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스
AU2022421751A1 (en) * 2021-12-21 2024-08-08 Curigin Co.,Ltd. Immune-cloaking antitumor adenovirus
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
CN115624524B (zh) * 2022-10-25 2023-10-27 中国医科大学附属第一医院 Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
EP1240337B1 (en) * 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU5882801A (en) 2000-05-26 2001-12-03 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
WO2007050128A2 (en) 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
HRP20100228T1 (hr) 2006-04-28 2010-07-31 The Trustees Of The University Of Pennsylvania Modificirani hekson protein adenovirusa i njegove uporabe
EP2176295B1 (en) * 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN101781636A (zh) * 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
JP5785607B2 (ja) 2010-04-14 2015-09-30 モガム バイオテクノロジー リサーチ インスティチュート サルアデノウイルス血清型19から単離されたヘキソン、その超可変領域、およびそれらを用いるキメラアデノウイルス
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety

Similar Documents

Publication Publication Date Title
JP2017514483A5 (cg-RX-API-DMAC7.html)
RU2016146664A (ru) Аденовирус, содержащий альбумин-связывающий участок
JP5075839B2 (ja) 癌の処置のための腫瘍崩壊性アデノウイルス
ES2167365T5 (es) Vectores adenovirales de origen animal y utilizacion en terapia genica.
Raty et al. Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications
ES2466415T3 (es) Construcción de recombinante de adenovirus oncolítico que expresa específicamente el factor inmunomodulador GM-CSF en células tumorales y usos del mismo
Kaplan Adenovirus-based cancer gene therapy
JP2014516536A5 (cg-RX-API-DMAC7.html)
Xiao et al. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo
Yokoda et al. Oncolytic virotherapy in upper gastrointestinal tract cancers
JP2022500013A (ja) グリコーゲンシンターゼキナーゼ−3(gsk3)のコード領域を含む複製能力ある組換えウイルス及び異常細胞を殺す方法
NZ537631A (en) Oncolytic virus replicating selectively in tumor cells
Sutter et al. Gene therapy for gastric cancer: is it promising?
JP2021500880A5 (cg-RX-API-DMAC7.html)
Ulasov et al. Oncolytic adenoviruses: a thorny path to glioma cure
Lundstrom Application of viruses for gene therapy and vaccine development
Yao et al. Current targeting strategies for adenovirus vectors in cancer gene therapy
JP2004505633A (ja) アデノウイルスe1b−55k単一アミノ酸変異体および使用方法
JP2013531681A5 (cg-RX-API-DMAC7.html)
Davis et al. Application of oncolytic viruses for cure of colorectal cancer
Qi et al. Anti-Tumor Effect of a Novel Oncolytic Virus Based on Chimpanzee Adenovirus Type 6
Curiel et al. Applications of viruses for cancer therapy
JP2022553870A (ja) 複製促進腫瘍溶解性アデノウイルス
Alemany Molecular design of oncolytic adenoviruses
Garcia-Aragoncillo et al. Design of virotherapy for effective tumor treatment